Paul Peter Tak

CIK: 0001873905

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (58.3%)

Position reduction

Option Exercises (M)2 (16.7%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CADL

Candel Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

CADL
Candel Therapeutics, Inc.
Sep 11, 2026
Sale(S)
Direct
59.4K shares at avg. $10.46$621K
CADL
Candel Therapeutics, Inc.
Sep 10, 2026
Exercise(M)
Direct
125K shares at avg. $1.55$194K
CADL
Candel Therapeutics, Inc.
Sep 10, 2026
Sale(S)
Direct
220.9K shares at avg. $11.50$2.5M
CADL
Candel Therapeutics, Inc.
Jan 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
629K shares-
CADL
Candel Therapeutics, Inc.
Jun 25, 2025
Award(A)
Direct
42.8K shares at avg. $4.67$200K
CADL
Candel Therapeutics, Inc.
Mar 19, 2025
Sale(S)
Direct
400 shares at avg. $9.00$4K
CADL
Candel Therapeutics, Inc.
Mar 18, 2025
Sale(S)
Direct
25.8K shares at avg. $8.77$226K
CADL
Candel Therapeutics, Inc.
Feb 12, 2025
Award(A)
Stock Option (Right to Buy)
Direct
525K shares-
CADL
Candel Therapeutics, Inc.
Jan 15, 2025
Sale(S)
Direct
21.7K shares at avg. $7.22$157K
CADL
Candel Therapeutics, Inc.
Jan 8, 2025
Sale(S)
Direct
21.2K shares at avg. $8.22$174K
CADL
Candel Therapeutics, Inc.
Nov 29, 2024
Sale(S)
Direct
48.8K shares at avg. $4.56$223K
CADL
Candel Therapeutics, Inc.
Nov 21, 2024
Exercise(M)
Direct
12.9K shares at avg. $1.55$20K

		Type	Shares	Price		Ownership
Sep 11, 2026	CADL Candel Therapeutics, Inc.	Sale(S)	59,379	$10.46	$620,891	Direct
Sep 10, 2026	CADL Candel Therapeutics, Inc.	Exercise(M)	125,000	$1.55	$193,750	Direct
Sep 10, 2026	CADL Candel Therapeutics, Inc.	Sale(S)	220,866	$11.50	$2,539,893	Direct
Jan 26, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	629,000	-	-	Direct
Jun 25, 2025	CADL Candel Therapeutics, Inc.	Award(A)	42,826	$4.67	$199,997	Direct
Mar 19, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	400	$9.00	$3,601	Direct
Mar 18, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	25,772	$8.77	$226,023	Direct
Feb 12, 2025	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	525,000	-	-	Direct
Jan 15, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	21,704	$7.22	$156,811	Direct
Jan 8, 2025	CADL Candel Therapeutics, Inc.	Sale(S)	21,172	$8.22	$173,996	Direct
Nov 29, 2024	CADL Candel Therapeutics, Inc.	Sale(S)	48,847	$4.56	$222,527	Direct
Nov 21, 2024	CADL Candel Therapeutics, Inc.	Exercise(M)	12,900	$1.55	$19,995	Direct

1-12 of 12 transactions

About Tak Paul Peter

Tak Paul Peter (SEC CIK 0001873905) files insider reports with the SEC as Chief Executive Officer of Candel Therapeutics, Inc. (CADL).

Signal8 holds 9 ownership filings by Tak Paul Peter, all Form 4s, filed between Nov 21, 2024 and Sep 11, 2026. Those filings report 12 transactions, from Nov 21, 2024 to Sep 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tak Paul Peter's filings is in NEEDHAM, MA.

Recent filings by Tak Paul Peter

Sep 11, 2026: Open-market sale of CADL shares (Form 4, code S).
Sep 10, 2026: Option exercise of CADL shares (Form 4, code M).
Sep 10, 2026: Open-market sale of CADL shares (Form 4, code S).
Jan 26, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 25, 2025: Grant or award of CADL shares (Form 4, code A).

Other insiders filing for Candel Therapeutics, Inc. (CADL)

Loggia Nicoletta, Director
PAPA JOSEPH C, Director
Manning Paul B, Director
Zimmermann Martine, Director
Tyagarajan Seshu, Chief Technology Officer
Sims Mark E., Chief Commercial Officer

How to read Form 4 transaction codes